FI88808B - Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma - Google Patents

Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma Download PDF

Info

Publication number
FI88808B
FI88808B FI863375D FI863375D FI88808B FI 88808 B FI88808 B FI 88808B FI 863375 D FI863375 D FI 863375D FI 863375 D FI863375 D FI 863375D FI 88808 B FI88808 B FI 88808B
Authority
FI
Finland
Prior art keywords
antibody
cells
monoclonal antibody
antibodies
human
Prior art date
Application number
FI863375D
Other languages
English (en)
Finnish (fi)
Other versions
FI88808C (sv
Inventor
Ingegerd Hellstroem
Joseph P Brown
Karl E Hellstroem
Diane Horn
Peter Linsley
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/684,759 external-priority patent/US4935495A/en
Application filed by Oncogen filed Critical Oncogen
Publication of FI88808B publication Critical patent/FI88808B/sv
Application granted granted Critical
Publication of FI88808C publication Critical patent/FI88808C/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (10)

1. Förfarande för producering av monoklonala antikroppar, kannetecknat av att (i) cellen som producerar monoklonala antikroppar identi- ·. fieras (hybridomas depositionsnummer ATCC HB8677), i vilka bindningsstället för antigenen förbinder sig tili (a) en kolhydratantigen, som liknar ganglio-N-triocylcera-mid, som markeras asialo-GM2, men är inte identisk därmed, och som är cellens ytdeterminant av människans icke-smäcel-liga lungcarcinoma; och (b) en proteinantigen, vars molekylvikt är cirka 30 000 dal-ton och som är associerad med människans icke-smäceliiga lungkarcinoma; (ii) cellen odlas under omständigheter, i vilka monoklonala antikroppar uppkommer; och (iii) de monoklonala antikropparna utvinns frän odlingen i “ steg (ii).
2. Förfarande enligt patentkravet 1, känneteckn&t av att monoklonala antikroppar omfattar en Fab-, F(ab')2- eller Fv-fragment därav. 28 r. r n r C· L o
3. Förfarande enligt patentkravet 1, kännetecknat av att de monoklonala antikropparna är konjugerade med ett stämpel, som är kapabelt att producera en detekterbar signal.
4. Förfarande enligt patentkravet 3, kännetecknat av att stämplet är ett fluoriserande ämne, radiostämpel, kromofor eller enzym.
5. Förfarande enligt patentkravet 2, kännetecknat av att fragmenten av den monoklonala antikroppen är konjugerad med ett stämpel, som är kapabelt att producera en detekterbar signal.
6. Förfarande enligt patentkravet 5, kännetecknat av att stämplet är ett fluoriserande ämne, radiostämpel, kromofor eller enzym.
7. Förfarande enligt patentkravet 1, kännetecknat av att den monoklonala antikroppen är av IgG-isotyp. • ·
8. Förfarande enligt patentkravet 1, kännetecknat av att den monoklonala antikroppen är av IgG2a-isotyp.
9. Förfarande enligt patentkravet 8, kännetecknat av att den monoklonala antikroppen markeras L6.
10. Förfarande enligt patentkravet 1, kännetecknat av att de monoklonala antikropparna produceras med musens hybrido-macellinje, som är deponerad i ATCC med identifikätions-egenskaper av HB8677. I i
FI863375D 1984-12-21 1986-08-20 Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma FI88808C (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68475984 1984-12-21
US06/684,759 US4935495A (en) 1984-12-21 1984-12-21 Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
US06/776,321 US4906562A (en) 1984-12-21 1985-10-18 Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US77632185 1985-10-18
US8502441 1985-12-13
PCT/US1985/002441 WO1986003838A1 (en) 1984-12-21 1985-12-13 Monoclonal antibodies and antigen for human non-small cell lung carcinomas

Publications (2)

Publication Number Publication Date
FI88808B true FI88808B (sv) 1993-03-31
FI88808C FI88808C (sv) 1993-07-12

Family

ID=27103432

Family Applications (2)

Application Number Title Priority Date Filing Date
FI863375D FI88808C (sv) 1984-12-21 1986-08-20 Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma
FI863375A FI98736C (sv) 1984-12-21 1986-08-20 Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI863375A FI98736C (sv) 1984-12-21 1986-08-20 Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma

Country Status (23)

Country Link
US (1) US4906562A (sv)
EP (1) EP0207963B1 (sv)
JP (1) JPH09191878A (sv)
KR (1) KR910000956B1 (sv)
AT (1) ATE77701T1 (sv)
AU (1) AU601360B2 (sv)
CA (1) CA1335796C (sv)
DE (1) DE3586262T2 (sv)
DK (1) DK168049B1 (sv)
ES (2) ES8800602A1 (sv)
FI (2) FI88808C (sv)
GB (1) GB2180256B (sv)
GR (1) GR853054B (sv)
HU (1) HUT42637A (sv)
IE (1) IE58572B1 (sv)
IL (1) IL77291A (sv)
NO (1) NO174718C (sv)
NZ (1) NZ214542A (sv)
OA (1) OA08412A (sv)
PH (1) PH25742A (sv)
PT (1) PT81744B (sv)
WO (1) WO1986003838A1 (sv)
YU (1) YU45294B (sv)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
EP0173648A3 (en) * 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
IL76877A (en) * 1984-11-02 1991-11-21 Oncogen Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
AU601680B2 (en) * 1985-05-28 1990-09-20 Joseph P. Brown Monoclonal antibodies for human non-small cell lung carcinomas
EP0234122A3 (en) * 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
AU632469B2 (en) * 1988-04-04 1993-01-07 Johns Hopkins University, The A method for early detection of lung cancer
US5173292A (en) * 1988-06-14 1992-12-22 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies which specifically recognize galactosyl-globoside, compositions containing same and methods of using same
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5192551A (en) * 1989-05-02 1993-03-09 Johns Hopkins University Neutral glycolipid as an adsorbent for enteric viral pathogens
CA2015862A1 (en) * 1989-05-04 1990-11-04 Gajanan Nilaver Cell surface antigen that binds with l6 monoclonal antibody
CA2040513A1 (en) * 1990-04-16 1991-10-17 Robert C. Bast, Jr. Method of diagnosing cancer
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5597707A (en) * 1993-04-15 1997-01-28 Bristol-Myers Squibb Company Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use
US7745159B2 (en) * 1999-02-26 2010-06-29 Nathalie B Scholler Methods and compositions for diagnosing carcinomas
US6117981A (en) * 1999-06-03 2000-09-12 Cytoclonal Pharmaceutics, Inc. Hybridomas for lung cancer marker and monoclonal antibodies thereof
EP1320551A4 (en) * 2000-09-01 2006-12-20 Internat Bioimmune Systems Inc IDENTIFICATION AND DEVELOPMENT OF SPECIFIC MONOCLONAL ANTIBODIES OF SPINOCELLULAR EPITHELIOMA
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP2298815B1 (en) * 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2743487A1 (en) * 2008-11-13 2010-05-20 Emergent Product Development Seattle, Llc Cd37 immunotherapeutic combination therapies and uses thereof
DK2768308T3 (en) 2011-10-14 2018-07-23 The Board Of Trustees Of The Univ Of Illionis COMPOUNDS AND ANTI-TUMOR-NQO1 SUBSTRATES
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
ES2853973T3 (es) * 2013-04-09 2021-09-20 The Board Of Trustees Of The Univ Of Illionis Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507391A (en) * 1982-04-02 1985-03-26 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
JPS6057254A (ja) * 1983-09-09 1985-04-03 Dainabotsuto Kk 免疫学的測定法による糖脂質の定量方法
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
IL76877A (en) * 1984-11-02 1991-11-21 Oncogen Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
JPS61258173A (ja) * 1985-05-10 1986-11-15 Akira Taniuchi モノクロ−ナル抗体およびその製法ならびに用途
AU601680B2 (en) * 1985-05-28 1990-09-20 Joseph P. Brown Monoclonal antibodies for human non-small cell lung carcinomas

Also Published As

Publication number Publication date
NO863071L (no) 1986-07-29
KR910000956B1 (ko) 1991-02-19
JPH09191878A (ja) 1997-07-29
KR870700139A (ko) 1987-03-14
ES8707797A1 (es) 1987-08-16
PH25742A (en) 1991-10-18
FI88808C (sv) 1993-07-12
NO174718C (no) 1994-06-22
FI863375A0 (sv) 1986-08-20
YU45294B (en) 1992-05-28
GR853054B (sv) 1986-04-15
OA08412A (en) 1988-06-30
DK393886D0 (da) 1986-08-19
GB2180256A (en) 1987-03-25
GB2180256B (en) 1989-08-31
EP0207963A1 (en) 1987-01-14
IE853220L (en) 1986-06-21
US4906562A (en) 1990-03-06
FI98736C (sv) 1997-08-11
HUT42637A (en) 1987-07-28
YU199685A (en) 1988-12-31
ES8800602A1 (es) 1987-11-16
NO174718B (no) 1994-03-14
AU5312486A (en) 1986-07-22
NZ214542A (en) 1991-07-26
GB8619900D0 (en) 1986-09-24
DE3586262D1 (de) 1992-07-30
EP0207963A4 (en) 1988-08-29
WO1986003838A1 (en) 1986-07-03
DK393886A (da) 1986-08-19
FI863375A (sv) 1986-08-20
EP0207963B1 (en) 1992-06-24
FI98736B (sv) 1997-04-30
ES550251A0 (es) 1987-11-16
NO863071D0 (no) 1986-07-29
IE58572B1 (en) 1993-10-06
ATE77701T1 (de) 1992-07-15
PT81744B (pt) 1987-11-30
DE3586262T2 (de) 1992-12-10
IL77291A (en) 1992-01-15
ES557140A0 (es) 1987-08-16
DK168049B1 (da) 1994-01-24
AU601360B2 (en) 1990-09-13
PT81744A (en) 1986-01-02
CA1335796C (en) 1995-06-06

Similar Documents

Publication Publication Date Title
FI88808B (sv) Förfarande för framställning av monoklonala antikroppar mot människansicke-småcelliga lungcarcinoma
JP2589682B2 (ja) ヒト非▲下−▼小細胞肺癌に関するモノクローナル抗体および抗原
US4737579A (en) Monoclonal antibodies for human non-small cell lung carinomas
US5185432A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
FI85814C (sv) Förfarande för producering av en monoklonal antikropp för humana icke- litencellslungcancer
FI87578C (sv) Förfarande för framställning av monoklonala antikroppar för ej-småcell iga lungkräftsvulster hos människa
WO1988002117A1 (en) Monoclonal paratopic molecule directed to human ganglioside gd2
AU601680B2 (en) Monoclonal antibodies for human non-small cell lung carcinomas
FI94291C (sv) Monoklonal antikropp

Legal Events

Date Code Title Description
MM Patent ceased/ lapsed

Owner name: ONCOGEN